• Acrivon Therapeutics outlined plans for initial development of ACR-525, its Phase 2-ready oral selective JAK1 inhibitor, in eosinophilic esophagitis.
• Phase 1 healthy volunteer studies showed dose-proportional pharmacokinetics with no serious adverse events; clinical data support once-daily dosing.
• Preclinical testing showed protection against IL-13- and OSM-induced epithelial barrier damage, broader activity than dupilumab.
• ACR-525 is wholly owned, with no milestone or royalty obligations; composition-of-matter protection extends to 2038, with extension opportunities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.